cas 939768-64-6|| where to buy cis-tert-Butyl 3-hydroxycyclobutanecarboxylate

Nombre del producto:cis-tert-Butyl 3-hydroxycyclobutanecarboxylate

IUPAC Name:tert-butyl (1s,3s)-3-hydroxycyclobutane-1-carboxylate

Unidad de embalaje	Stock disponible	Precio($)
CM202687-250mg	in stock	ũǜ
CM202687-1g	in stock	Ȑũŵ
CM202687-5g	in stock	ũŵũ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 939768-64-6 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :939768-64-6; Fórmula molecular:C9H16O3; Punto de fusión:-; Código de sonrisas:O=C([C@H]1C[C@@H](O)C1)OC(C)(C)C; Densidad:

: Número de catálogo:CM202687; Peso molecular:172.22; Punto de ebullición:; Nº Mdl:MFCD20259656; Almacenamiento:Store at 2-8°C.

: Cyclobutanes; The molecular structure of cyclobutane has four carbon atoms, and its four carbon atoms are not in the same plane, which is the folded conformation of cyclobutane. Cyclobutane itself is not of commercial or biological interest, but more complex derivatives are important in biology and biotechnology. Currently, nine FDA-approved drugs contain the cyclobutane structure. From the perspective of therapeutic areas, cyclobutyl drugs are mainly distributed in popular areas such as tumors, neurological diseases, infectious diseases, endocrine and metabolic diseases.

: DNL343; Denali Therapeutics announces completion of enrollment for regimen G evaluating eIF2B agonist DNL343 in the phase 2/3 HEALEY ALS platform trial. Amyotrophic lateral sclerosis (ALS) causes progressive nerve degeneration in the spinal cord and brain, representing a large unmet medical need. The activation of integrated stress response (ISR) is documented in ALS patients, resulting in the suppression of eukaryotic translation initiation factor 2B (eIF2B) activity, and impaired protein synthesis.
Denali's ALS therapy DNL343 is an investigational small molecule eIF2B activator. It is designed to restore protein synthesis and inhibit ISR pathway in ALS. The compound is found to be generally well-tolerated and support once-daily dosing.